A single-cell atlas of CD19 chimeric antigen receptor T cells.

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2023-11-13 Epub Date: 2023-09-21 DOI:10.1016/j.ccell.2023.08.015

Xubin Li, Jared Henderson, Max J Gordon, Irtiza Sheikh, Loretta J Nastoupil, Jason Westin, Christopher Flowers, Sairah Ahmed, Linghua Wang, Sattva S Neelapu, Paolo Strati, Qing Deng, Michael R Green

引用次数: 1

Abstract

Li et al. present a resource of single-cell RNA sequencing (scRNA-seq) data from the infusion products of relapsed or refractory large B cell lymphoma (rrLBCL) patients treated with standard-of-care axicabtagene ciloleucel and identify features that are significantly different between products from responders and non-responders at 3-month followup by PET/CT, an important landmark for long-term outcomes.

查看原文本刊更多论文

CD19嵌合抗原受体T细胞的单细胞图谱。

李等。提供了来自接受标准护理阿昔卡他啶西洛ucel治疗的复发或难治性大B细胞淋巴瘤（rrLBCL）患者输注产品的单细胞RNA测序（scRNA-seq）数据资源，并在PET/CT的3个月随访中确定了应答者和无应答者产品之间显著不同的特征，这是长期结果的重要里程碑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.